Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Exclusion Criteria

• •1\. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma;
• •2\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
• •3\. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP\>160mmHg or DBP\>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;
• •4\. Postoperative complications such as bleeding, pancreatic fistula, gastric obstruction, abdominal infection, and biliary fistula, which made the patient unable to receive adjuvant therapy within 12 weeks after surgery;
• •5\. CA199\>180 U/ml within 21d before adjuvant therapy;
• •6\. Known allergy to prescription or any component of the prescription used in this study;
• •7\. Known HIV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);
• •8 .Other reasons that are not suitable to participate in this study according to the researcher\'s judgment.